Oncology

A new drug designed to counter the effects of an important, but very hard to target, cancer mutation could be effective against a range of tumour types including lung and gynaecological cancers, a new clinical trial shows. Researchers used an innovative, intermittent treatment schedule to limit the drug’s toxicity, and found responses in over a […]

MATWIN, a French platform dedicated to promoting innovation in oncology, has selected six projects  it believes offer the most promising opportunities for patients in the fight against cancer. The MATWIN board is the only committee of its kind in Europe. It brings together around 20 members including 13 leading global industrial decision makers in oncology […]

Immunai has joined forces with Baylor College of Medicine to bring more targeted and effective cancer therapies to market. Leveraging Immunai’s single-cell technology and artificial intelligence, Baylor and Immunai will analyse natural killer T (NKT) cells and genetically engineer them into immunotherapies that target a variety of cancers, including solid tumours. While some immunotherapies like […]

Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows. It is the first trial to use the pioneering genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together with a promising new medicine, […]

Backed by more than 20 years of research and development expertise, Concarlo Holdings is developing diagnostics and therapeutics that could have huge impact for metastatic breast cancer patients. Lu Rahman finds out more. Stacy Blain, Co-Founder, Concarlo Holdings, wants to change the conversation around breast cancer. This biotechnology start-up whose technologies aim to diagnose and […]

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 – Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Currently, there is a huge […]

Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. This new understanding could enable […]

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver in many diseases. In cancer research, significant advances have been made in defining druggable […]

Gaining Insights Into Disease Biology for Target Identification and Validation Sponsored by Agilent Dysfunctional energy metabolism is associated with many different diseases. As such, metabolic modulation is a promising avenue for novel targets in cancer, immunology, and neurological disease. Learn how live-cell metabolic measurements generate critical information about pathways and nutrients used to produce ATP […]

The Opencorona consortium has awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak. Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, announced on March 30, they have been awarded €3 million emergency funding […]